A.P. Pharma Puts Off APF530 Launch To 2014 After Another FDA Rejection
This article was originally published in Pharmaceutical Approvals Monthly
A.P. Pharma faces a second commercial setback as FDA issues another “complete response” letter for its long-acting granisetron in chemotherapy-induced nausea and vomiting.
You may also be interested in...
Heron Therapeutics gained approval of its chemotherapy-induced nausea and vomiting drug Sustol (granisetron), but the company faces stiff competition and postmarketing requirements. Analysts, nonetheless, think the product has a bright future on the US market.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.